Affiliation: University of South Florida
- A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancyAndy Trotti
Radiation Oncology Program, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
Int J Radiat Oncol Biol Phys 58:674-81. 2004..It is hypothesized that infection plays a role in the development of OM. We tested the efficacy of iseganan HCl (iseganan), a synthetic peptide with broad-spectrum antimicrobial activity, for preventing RT-associated OM...
- The evolution and application of toxicity criteriaAndy Trotti
H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
Semin Radiat Oncol 12:1-3. 2002..Just as the revised CTC has provided a new common standard for the grading of acute effects, a similar effort is needed in the late effects area. The creation of a unified late effects system is under active development...
- Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultationYuhchyau Chen
Department of Radiation Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 8647, USA
Int J Radiat Oncol Biol Phys 64:1442-51. 2006....
- Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI)A Trotti
Division of Radiation Oncology, and the Biostatistics Core, University of South Florida, James A Haley VA Medical Center, Tampa, USA
Int J Radiat Oncol Biol Phys 42:257-61. 1998..The goal was to create a more complete, yet concise, head and neck site-specific module geared toward patients receiving radiation therapy for head and neck cancer...
- TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology GroupAndy Trotti
H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612 9497, USA
Lancet Oncol 8:613-24. 2007....
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentAndy Trotti
H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA
Semin Radiat Oncol 13:176-81. 2003..This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0...
- Toxicity in head and neck cancer: a review of trends and issuesA Trotti
Division of Radiation Oncology, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
Int J Radiat Oncol Biol Phys 47:1-12. 2000..Further research into the assessment and analysis of toxicity is not only crucial to improvements in quality of life (QOL), but perhaps, improved rates of disease control as well...
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyA Trotti
H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
Int J Radiat Oncol Biol Phys 47:13-47. 2000..CTC v. 2.0 represents an improvement in the evaluation and grading of acute toxicity for all modalities...
- Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature reviewAndy Trotti
Radiation Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
Radiother Oncol 66:253-62. 2003..To determine the frequency of mucositis and associated outcomes in patients receiving radiotherapy (RT) for head and neck cancer through a systematic review of recently published literature...
- Patient-reported outcomes and the evolution of adverse event reporting in oncologyAndy Trotti
Division of Radiation Oncology, H Lee Moffitt Cancer Center at University of South Florida, Tampa, FL 33612 9416, USA
J Clin Oncol 25:5121-7. 2007..Therefore, care must be used when developing health outcomes and safety data collection plans...
- Assessment of toxicity in cooperative oncology clinical trials: the long and short of itClement K Gwede
Dept of Interdisciplinary Oncology, University of South Florida and H Lee Moffitt Cancer Center and Research Institute, Tampa, USA
J Oncol Manag 11:15-21. 2002..The potential implications for toxicity data management practices, data quality, patient care management and resource utilization are discussed...
- Skin changesGloria Wood
Radiation Therapy, H Lee Moffitt Cancer Center, Tampa, FL, USA
Cancer Treat Res 128:171-81. 2006..Ongoing research studying acute and late skin effects works to minimize reactions and improve patient quality-of-life. However, research with strong methodology is needed to determine if any management strategy is superior...
- Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysisTawee Tanvetyanon
Head and Neck Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
Am J Otolaryngol 30:38-43. 2009..Squamous cell carcinoma (SCC) is associated with IP in about 7% of cases. To date, there has been no pooled analysis to formulate a survival outcome associated with this rare condition...
- Local excision of T2 and T3 rectal cancers after downstaging chemoradiationC J Kim
Department of Surgery, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
Ann Surg 234:352-8; discussion 358-9. 2001....
- The need for adverse effects reporting standards in oncology clinical trialsAndy Trotti
J Clin Oncol 22:19-22. 2004
- Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventionsSøren M Bentzen
University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 69:S79-82. 2007
- Complications of radiation therapy for head and neck cancers. The patient's perspectiveAlison M Rose-Ped
Empirica, Inc, Portland, Ore 97225, USA
Cancer Nurs 25:461-7; quiz 468-9. 2002..Trends toward more aggressive management of head and neck cancers underscore the need for new and effective therapies for oropharyngeal mucositis occurring in patients receiving radiotherapy...
- Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14K Kian Ang
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 97, Houston, TX 77030, USA
J Clin Oncol 23:3008-15. 2005..To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC)...
- P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003E Hammond
LDS Hospital, Salt Lake City, UT 84143, USA
Int J Radiat Oncol Biol Phys 57:683-92. 2003..We sought to confirm this finding by analyzing patients entered on RTOG 9003, a Phase III randomized trial of altered fractionation radiotherapy...
- Head and neck cancer: recent advances and new standards of careArlene A Forastiere
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Clin Oncol 24:2603-5. 2006
- Evaluation of new treatments in radiation oncology: are they better than standard treatments?Heloisa P Soares
H Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa 33612, USA
JAMA 293:970-8. 2005..To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention...
- Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy AgencySusan E Davidson
Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
Int J Radiat Oncol Biol Phys 69:1218-21. 2007....
- Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancerArlene A Forastiere
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
N Engl J Med 349:2091-8. 2003..The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown...
- Adverse effects: a Pandora's box for oncologyAndy Trotti
Int J Radiat Oncol Biol Phys 54:642-6. 2002
- Treatment of head and neck cancerAndy Trotti
N Engl J Med 358:1076; author reply 1077-8. 2008
- Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14)Adam S Garden
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 71:1351-5. 2008..This article reports the long-term toxicity, relapse patterns, and survival in patients with advanced head and neck carcinoma...